Indianapolis, IN Clinical Trials Report — April 2026

For individuals in Indianapolis considering participation in clinical research, April 2026 presents a critical window for those looking to join studies before enrollment concludes. Across the city, 64 clinical trials are slated to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 5 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

New Opportunities and Notable Research

This month, Indianapolis saw the opening of 5 new clinical trials, a decrease from the 13 trials that launched in March 2026. Despite this dip in new openings, the city continues to be a vital center for medical research, with a total of 854 clinical trials currently recruiting across 388 research facilities.

April brings several significant new trials to Indianapolis, including important Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Memorial Sloan Kettering Cancer Center is sponsoring NCT07507643, "A Study of Methylprednisolone in People Having Liver Surgery." This Phase 3 study, aiming for 750 participants, investigates whether methylprednisolone administered before surgery can reduce side effects such as infections and shorten hospital stays.
• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy.
• Eli Lilly and Company is initiating NCT07533019, "A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo." This Phase 2 study, designed for 60 participants, will evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV).

The new trials cover a variety of conditions, including:

• ADHD - Attention Deficit Disorder with Hyperactivity
• Anxiety Disorders
• Depressive Disorder, Major
• Hepatectomy
• Netherton Syndrome
• Non-Segmental Vitiligo (NSV)
• Pregnancy Complications
• Pregnancy, High Risk
• Solid Tumors
• Stress Disorders, Post-Traumatic

Of the 5 new trials, 4 are drug trials and 1 is a behavioral trial. Industry sponsors account for 3 of these new studies, with the remaining 2 sponsored by other organizations, including academic institutions like Indiana University and Memorial Sloan Kettering Cancer Center.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to medical research in Indianapolis. While none of the 5 new trials launched this month are actively seeking healthy volunteers, a total of 69 clinical trials are currently recruiting healthy participants across the city. These studies provide numerous avenues for those interested in supporting medical advancements without having a particular health condition.

Impending Deadlines for Specific Conditions

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on heart conditions, advanced cancers, and neurological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Heart Failure (2 trials)
• Advanced Solid Tumor (2 trials)
• Neuroblastoma (2 trials)
• Stage IV Lung Cancer AJCC V8 (2 trials)
• Adult Urological Procedures (1 trial)
• Advanced Lung Non-Small Cell Carcinoma (1 trial)
• Adult Gynecological Procedures (1 trial)
• Alzheimer Disease (1 trial)
• Adult Thoracic Procedures (1 trial)
• Ambulatory Heart Failure, NYHA Class IV (1 trial)

Indianapolis's Leading Research Facilities

Indianapolis is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Indiana University (104 trials)
• Riley Hospital for Children (66 trials)
• Indiana University School of Medicine (44 trials)
• Indiana University/Melvin and Bren Simon Cancer Center (41 trials)
• Indiana University Melvin and Bren Simon Comprehensive Cancer Center (23 trials)
• Indiana University Health University Hospital (20 trials)
• Community Health Network (20 trials)
• IU Health Methodist Hospital (20 trials)
• Dawes Fretzin Clinical Research Group, LLC (18 trials)
• Indiana University Health (18 trials)
• Saint Catherine Hospital (17 trials)
• Ascension Saint Vincent Indianapolis Hospital (16 trials)

Indiana University and its associated medical centers and hospitals collectively represent the largest hub for clinical research in the city, offering a broad spectrum of studies from pediatric care at Riley Hospital for Children to oncology at the Melvin and Bren Simon Cancer Centers.

Broadening Your Search: Nearby Indiana Options

While Indianapolis offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Indiana. Cities with active trials include:

• Bloomington (1 trial)
• Muncie (1 trial)
• New Albany (1 trial)
• West Lafayette (1 trial)

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 5 new trials launched this month, 1 includes children and 5 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is specifically designed for female participants. The landscape of new trials shows a continued focus on drug development, with major sponsors like Eli Lilly and Company and Incyte Corporation driving significant research efforts alongside academic institutions.

As we move into the spring, the focus will remain on the ongoing enrollment in these significant Phase 2 and Phase 3 trials and the continued exploration of new therapeutic strategies, with Indianapolis's robust research community at the forefront of medical innovation.